The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas.
P. Y. Wen
Research Funding - Merck
V. K. Puduvalli
No relevant relationships to disclose
J. G. Kuhn
No relevant relationships to disclose
J. M. Reid
No relevant relationships to disclose
K. Lamborn
No relevant relationships to disclose
T. F. Cloughesy
No relevant relationships to disclose
S. M. Chang
No relevant relationships to disclose
J. Drappatz
No relevant relationships to disclose
W. K. A. Yung
No relevant relationships to disclose
M. R. Gilbert
Consultant or Advisory Role - Genentech; Sigma-Tau
Honoraria - Genentech; Merck; Sigma-Tau
Research Funding - Genentech; Merck
H. I. Robins
No relevant relationships to disclose
F. S. Lieberman
No relevant relationships to disclose
A. B. Lassman
No relevant relationships to disclose
R. M. McGovern
No relevant relationships to disclose
S. Desideri
No relevant relationships to disclose
X. Ye
No relevant relationships to disclose
M. M. Ames
No relevant relationships to disclose
I. J. Espinoza-Delgado
No relevant relationships to disclose
S. A. Grossman
No relevant relationships to disclose
M. Prados
No relevant relationships to disclose